1. Clinical Overview
Molecule: Synthetic α-MSH analog • Potent, stable MC1R agonist
Classification: Pigmentation peptide • Photoprotective agent • Anti-inflammatory neuropeptide • Melanocortin regulator • Mild sexual-function enhancer
MT-1 vs MT-2
| Feature | Melanotan-1 | Melanotan-2 |
|---|
| Primary use | Pigment / photoprotection | Libido, erection, pigment |
| Sexual effects | Mild | Strong |
| Nausea risk | Very low | Moderate/high |
| Tanning potency | Moderate | Strong |
| Safety profile | Superior | More side effects |
Melanotan-1 is the safer, more medically oriented version.
2. Mechanisms of Action
2.1 MC1R Activation → Melanogenesis
Selectively activates MC1R on melanocytes: ↑ tyrosinase, ↑ melanin/eumelanin, ↓ pheomelanin, ↑ melanosome distribution. Progressive deep, natural pigmentation with reduced UV susceptibility.
2.2 Photoprotective Effects
Increased melanin (natural UV filter), reduced DNA photodamage, increased antioxidant pathways, reduced free-radical generation. May reduce sunburn, photodermatitis, actinic injury.
2.3 Anti-Inflammatory & Immune
Reduces IL-1, IL-6, TNF-α, COX-2, pro-inflammatory eicosanoids. Supports autoimmune skin management, rosacea, UV-induced inflammation reduction.
2.4 Mild Sexual Enhancement
Acts mildly on MC3R/MC4R: sexual arousal, libido, erectile signaling (minor vs PT-141).
2.5 Appetite & Energy (Subtle)
Unlike MT-2: does not significantly suppress appetite, cause stretching/lethargy, or cause nausea in most users.
3. Evidence-Supported Applications
3.1 Pigmentation / Sunburn Prevention
Phototype I–III, easy burners, solar urticaria, polymorphic light eruption, vitiligo adjunct. Reduces sunburn severity, UV-induced DNA damage.
3.2 Cosmetic Tanning
Even, natural pigmentation. Reduces UV exposure need. Improves skin undertone.
3.3 Afamelanotide / Scenesse®
FDA-approved for EPP. Strong photoprotection, reduced phototoxic pain, increased sunlight tolerance. This guide covers SC injections, not implants.
3.4 Dermatologic & Anti-Inflammatory
Rosacea, psoriasis, atopic dermatitis, post-procedure erythema, UV-induced inflammation.
3.5 Mild Libido Support
Stress-related decline, perimenopausal arousal, mild erectile support (less potent than PT-141).
4. Administration & Protocols
4.1 Cosmetic / Pigmentation
Loading: 0.25–0.5 mg SC daily/EOD × 10–20 doses
Maintenance: 0.25–0.5 mg SC once weekly
Photoprotection Protocol
0.25–0.5 mg SC, 2–3×/week × 2–3 weeks → 0.25 mg weekly maintenance
For solar urticaria, photodermatoses, outdoor professions
Vitiligo Adjunct (Off-Label)
0.25 mg SC 2–3×/week + phototherapy • 8–16 week cycles
Timing & Pattern
Inject evenings if flushing occurs. Start lower in fair-skinned patients. Sun exposure enhances but not required. Gradual darkening over 2–4 weeks; pigmentation persists weeks to months.
5. Combination Therapy (Peptide Protocol Portal Synergy)
+ GHK-Cu: Dermal repair + even pigmentation + anti-aging
+ SNAP-8 + Argireline: Wrinkle reduction + complexion + skin tone
+ PT-141: Strong libido/arousal + mood stability
+ KPV: Anti-inflammatory + melanocortin immune modulation (rosacea, post-procedure)
+ Glutathione: Tone balancing — glutathione lightens toxic pigmentation while MT-1 darkens melanin distribution
6. Clinical Decision Trees
Decision Tree 1 — Is MT-1 Indicated?
Increased pigmentation/tanning goal? → YES
Burns easily / photodermatitis? → YES
Photoprotection needed? → YES
Vitiligo adjunct? → YES (with phototherapy)
Libido enhancement? → Mild; consider PT-141 instead
Concern for nausea/flushing? → MT-1 preferred over MT-2
Decision Tree 2 — Dose Selection
Fair skin (I–II) → 0.25 mg EOD
Medium skin (III–IV) → 0.25–0.5 mg daily
Maintenance → 0.25 mg weekly
Photoprotection → 0.25–0.5 mg 2–3×/week
7. Integrated Treatment Archetypes
Archetype A — Tanning / Pigmentation
Systemic: MT-1 0.25–0.5 mg EOD + low UV 1–2×/week (optional)
Topical: GHK-Cu + hyaluronic acid
Archetype B — Medical Photoprotection
Systemic: MT-1 0.25–0.5 mg SC 3×/week + KPV + Vitamin D
Outcome: Reduced phototoxic injury, improved sunlight tolerance.
Archetype C — Cosmetic Complexion
Systemic: MT-1 micro-dosing + Glutathione IV
Topical: GHK-Cu nightly + SNAP-8 AM
Outcome: Even pigmentation + anti-aging synergy.
Archetype D — Sexual-Function Support
Systemic: MT-1 0.25 mg SC ± PT-141 PRN + Kisspeptin
Outcome: Mild libido increase + enhanced intimacy.
8. Expected Timeline
3–5 days: Subtle warm undertone
7–14 days: Visible pigmentation
3–4 weeks: Full cosmetic tanning
4–8 weeks: Significant photoprotection
Maintenance: Weekly dosing preserves pigment
9. Contraindications
Absolute
- Pregnancy / Breastfeeding
- Personal or family history of melanoma
- Suspicious skin lesions (examine first)
Relative
- Phototoxic medications
- Severe hepatic disease
- History of dysplastic nevi
- Uncontrolled autoimmune disorders
10. Adverse Effects
Fewer side effects than MT-2. Common (mild): facial flushing, mild nausea, fatigue, warm sensation, headache. Less common: freckle/mole hyperpigmentation, temporary appetite suppression (rare), darkening of existing nevi (monitoring required).
11. Monitoring
- Dermatologic screening (baseline + periodic)
- Nevi monitoring (asymmetry, border, color)
- Phototype assessment
- Hydration & skin barrier
- Libido/mood changes (rare)
Legal Disclaimer
This document is provided solely for educational and informational purposes. Melanotan-1 and other peptides are not FDA-approved drugs. Peptide Protocol Portal makes no representations or warranties. By using this document, the reader agrees that Peptide Protocol Portal shall not be held liable. Use at your own risk.
References — Melanotan-1 Clinical Reference Guide
Foundational Melanocortin & MC1R
1. Cone, R. D. The central melanocortin system. Endocrine Reviews, 27(7), 736–749 (2006).
2. Abdel-Malek, Z. A., et al. Melanocortin receptor signaling. Pigment Cell Melanoma Res, 31(1), 5–24 (2018).
3. Suzuki, I., et al. Melanogenesis and DNA repair via MC1R. J Biol Chem, 277(5), 3854–3860 (2002).
4. Harrison, S., & Zouboulis, C. C. Pigmentation regulation by melanocortins. Dermato-Endocrinology, 8(1), e1135282 (2016).
MT-1 / Afamelanotide Pharmacology
5. Hadley, M. E., et al. Development of MT-1. Ann N Y Acad Sci, 994(1), 316–330 (2003).
6. Thody, A. J., et al. Melanocortin analogues on pigmentation. Br J Dermatol, 137(4), 665–672 (1997).
7. Luger, T. A., et al. α-MSH analogues in photoprotection. J Invest Dermatol, 126(10), 2356–2363 (2006).
8. Wikberg, J. E. S., et al. MT-1 vs MT-2 pharmacologic specificity. Eur J Pharmacol, 467(1–3), 149–160 (2003).
EPP Clinical Trials (Afamelanotide)
9. Langendonk, J. G., et al. Afamelanotide for EPP: Phase 3. NEJM, 373(1), 48–59 (2015).
10. Biolcati, G., et al. Long-term Afamelanotide in EPP. Br J Dermatol, 174(2), 414–418 (2016).
11. Minder, E. I., et al. Afamelanotide light tolerance in EPP. Photochem Photobiol, 91(2), 333–339 (2015).
12. Todd, J. J., & Gropper, D. Afamelanotide mechanism and trials. Expert Opin Pharmacother, 19(1), 1–11 (2018).
DNA Repair & Photoprotection
13. Kadekaro, A. L., et al. α-MSH reduces UV DNA damage. PNAS, 100(9), 5569–5574 (2003).
14. Bohm, M., et al. Melanocortins and DNA repair. Exp Dermatol, 13(S4), 22–26 (2004).
15. Schallreuter, K. U., et al. MT-1 enhances keratinocyte DNA repair. J Clin Invest, 115(6), 1522–1529 (2005).
Dermatology & Aesthetic
16. Pawlowski, A., et al. MT-1 vs UV melanogenesis. J Am Acad Dermatol, 62(1), AB34 (2010).
17. Hogan, D. J., et al. Afamelanotide improves melanin density. Photodermatol Photoimmunol Photomed, 30(5), 228–235 (2014).
18. Böhm, M., et al. Melanocortin analogues in dermatoses. J Eur Acad Dermatol Venereol, 28(2), 126–132 (2014).
19. Abdel-Malek, Z. A., et al. Eumelanin induction by α-MSH. Pigment Cell Res, 9(6), 265–270 (1996).
Anti-Inflammatory & Immunomodulatory
20. Lambeir, A.-M., et al. Anti-inflammatory melanocortin actions. Ann N Y Acad Sci, 994(1), 319–330 (2003).
21. Catania, A., et al. Melanocortin peptides and immune regulation. Endocrine Reviews, 25(5), 744–795 (2004).
22. Luger, T. A., & Scholzen, T. α-MSH immunomodulation in skin. J Invest Dermatol Symp Proc, 6(1), 1–7 (2001).
Metabolic & Neurological
23. Mountjoy, K. G. MC1R/MC4R systemic roles. Annu Rev Physiol, 72, 95–120 (2010).
24. Lindskog, S., et al. Melanocortin peptides and pain. Pain, 136(1–2), 136–145 (2008).
25. Zeng, Q., et al. α-MSH neuroprotection. Neurosci Lett, 362(2), 101–104 (2004).
Safety & Melanocyte Biology
26. Kadekaro, A. L., et al. MC1R protects melanocytes from UV. FASEB J, 24(10), 3856–3867 (2010).
27. Abdel-Malek, Z., et al. Melanocortins reduce oxidative DNA damage. Pigment Cell Res, 14(4), 250–257 (2001).
28. Wong, T. H., et al. Melanocortin analog safety in melanoma models. Melanoma Research, 21(3), 167–175 (2011).
Regulatory & Clinical
29. FDA CDER. Afamelanotide (SCENESSE®) approval. U.S. FDA, 2024.
30. Langendonk, J. G., & Balwani, M. EPP management: Afamelanotide. Hematol Oncol Clin N Am, 33(3), 363–372 (2019).